Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats.
Recent reports suggest that the effect of photodynamic therapy (PDT) can be enhanced by fractionating the light dose or reducing the light fluence rate. We assessed these options on two tissues in rats (normal colon and a transplanted fibrosarcoma) using the photosensitiser meta-tetrahydroxyphenylchlorin (mTHPC). Animals were sensitised with 0.3 mg/kg mTHPC, 3 days prior to illumination with red light (652 nm) using a single fibre touching the target tissue and killed 1-3 days later for quantitative measurement of the extent of PDT necrosis. Results were similar for both tissues, although the differences between illumination regimens were less marked in tumour tissue. Using continuous illumination and a fixed low energy in colon, the extent of necrosis was up to almost three times larger with 5 mW than with 100 mW, although the maximum attainable necrosis was independent of power. The long treatment time using 5 mW could be halved without loss of effect by increasing the power during treatment. Dividing the light into two equal fractions at 100 mW increased the lesion size by up to 20% in colon (independent of the timing of the dark interval), but by only 10% in tumour and had no effect at 20 mW. Previous studies using 5-aminolaevulinic acid (ALA) showed a much larger effect of fractionation that was critically dependent on the timing of the dark interval. We postulate that enhancement of PDT by fractionation is due to improved oxygen supply to the treated area which may be due to reversal of temporary vascular occlusion (more likely with ALA) or less rapid photochemical consumption of oxygen (more likely with mTHPC). At lower fluence rates, the oxygen consumption rate is not fast enough to be improved by fractionation. We conclude that fractionated or low power light delivery can enhance PDT with mTHPC. Although the effects are not large, this may be of value for interstitial treatment of solid tumours when multiple sites are treated simultaneously.
Tsutsui
H
H
National Medical Laser Centre, Department of Surgery, Royal Free and University College Medical School, University college London, London, UK.
MacRobert
A J
AJ
Curnow
A
A
Rogowska
A
A
Buonaccorsi
G
G
Kato
H
H
Bown
S G
SG
D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy*; D008027:Light; D008652:Mesoporphyrins / Q000627:therapeutic use*; D023421:Models, Animal; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D051381:Rats
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; C072269:temoporfin